After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on the clinical effectiveness and cost effectiveness of technologies for the primary prevention of osteoporotic fragility fractures in postmenopausal women and alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women and submitted them to the Institute.

The FADs have been sent to the formal consultees for these appraisals who have 15 working days to consider whether they wish to appeal against them. Subject to any appeal by consultees, the FADs may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5pm on 9 July 2007.